Source facts
FDA issued a complete response letter. No controlled deficiency theme met the deterministic text-matching threshold; review the exact redacted letter.
US FDA source recordCRL · Complete Response Letter
FDA-regulated product — FDA Complete Response Letter
Issued to Chiesi Farmaceutici S.p.A. Application reviewed but not approved; deficiencies must be corrected.
Issued
February 27, 2026Product
FDA-regulated product
Company
Chiesi Farmaceutici S.p.A
Stage
Final Decision
Assyro regulatory brief
FreeWhat did FDA decide for FDA-regulated product?
Source facts and Assyro context are separated so you can scan the action quickly without treating analysis as an FDA conclusion.
Key details in this letter
No structured topic signal was identified. Review the source document directly.
Suggested next step
Review the exact redacted FDA letter and address each stated deficiency before resubmission.
Open the document workspaceFDA source document
Read the full FDA complete response letter (PDF)
Loading document viewer…
Common questions about the FDA-regulated product complete response letter
What does this complete response letter mean for FDA-regulated product?
Application reviewed but not approved; deficiencies must be corrected. Requires resubmission addressing deficiencies. FDA issued this letter to Chiesi Farmaceutici S.p.A on February 27, 2026.
What happens after an FDA complete response letter?
FDA will not approve the application in its present form. The sponsor can resubmit after addressing every deficiency listed in the letter — which starts a Class 1 (two-month) or Class 2 (six-month) resubmission review clock — withdraw the application, or request an opportunity for a hearing.